phenotypeId,phenotypeName,clinicalDescription,metaDataJson
192675000,Biliary cirrhosis,Overview: a disease of immune system with T-cell mediated attack on intralobular hepatic bile ducts. Presentation: Patients may be asymptomatic or may have signs and symptoms of cholestasis like fatigue to pruritus. Assessment: liver enzyme with alkaline phosphatase elevation. antimitochondrial antibodies (AMA) is considered serologic hallmark. Plan: symptom management. Disease progression may be slowed with ursodeoxycholic acid. Prognosis: long term disease that may progress with portal hypertension and/or hepatocellular carcinoma.,"{
	""oldPhenotypeId"" : [
		""192675000""
	],
	""newPhenotypeId"" : [
		""192675000""
	],
	""phenotypeId"" : [
		""192675000""
	],
	""phenotypeName"" : [
		""Biliary cirrhosis""
	],
	""referentConceptId"" : [
		""192675""
	],
	""clinicalDescription"" : [
		""Overview: a disease of immune system with T-cell mediated attack on intralobular hepatic bile ducts. Presentation: Patients may be asymptomatic or may have signs and symptoms of cholestasis like fatigue to pruritus. Assessment: liver enzyme with alkaline phosphatase elevation. antimitochondrial antibodies (AMA) is considered serologic hallmark. Plan: symptom management. Disease progression may be slowed with ursodeoxycholic acid. Prognosis: long term disease that may progress with portal hypertension and/or hepatocellular carcinoma.""
	],
	""literatureReview"" : [
		""""
	],
	""phenotypeNotes"" : [
		""""
	],
	""deprecate"" : [
		""""
	]
}"
